RemeOs is an MRI-compatible, absorbable hybrid composite and is designed for cervical spinal fusion, the company said in an Oct. 4 news release.
The company’s financial targets were also upgraded in light of the decision to accelerate RemeOs development. Bioretec increased its net sales forecast to more than $71 million by the end of 2028 and expects to see positive operational cash flow by the end of 2027 instead of 2026.
